The provided search query appears to be a partial reference to a patent application related to dasatinib. Without the full patent number or more context, it is not possible to provide specific details about its contents or status. However, general information about dasatinib patents can be discussed.
What is Dasatinib?
Dasatinib is a medication used to treat certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1]. It is a tyrosine kinase inhibitor that works by blocking the action of specific enzymes involved in cancer cell growth [1][2].
When Does Dasatinib Patent Protection End?
Patent protection for branded drugs like dasatinib prevents generic versions from entering the market. The original patents for dasatinib (Sprycel) have expired or are nearing expiry in various regions, paving the way for generic competition. For instance, U.S. patents related to dasatinib have faced litigation and have seen generic versions approved. The specific expiry dates and the impact of any patent challenges can be tracked through resources like DrugPatentWatch.com [3].
Who Makes Generic Versions of Dasatinib?
As patents expire, pharmaceutical companies can apply to regulatory agencies like the U.S. Food and Drug Administration (FDA) for approval to market generic versions of dasatinib. Several companies have developed or are developing generic dasatinib, which can lead to lower prices for the medication [4].
What Are the Risks of Generic Drug Substitution?
While generic drugs are designed to be bioequivalent to their brand-name counterparts, patients and healthcare providers may have concerns about switching from a brand-name medication to a generic. These concerns can include potential differences in inactive ingredients, formulation, or patient response, although regulatory bodies ensure generics meet strict standards for safety and efficacy [5].
How Does Dasatinib Compare to Other Leukemia Treatments?
Dasatinib is one of several targeted therapy options available for CML and Ph+ ALL. Other tyrosine kinase inhibitors, such as imatinib (Gleevec), nilotinib (Tasigna), and bosutinib (Bosulix), are also used. The choice of treatment depends on factors like the specific genetic mutations present in the cancer cells, the patient's medical history, and potential side effects [6][7].
What is the Latest Clinical Data for Dasatinib?
Ongoing clinical trials continue to evaluate dasatinib, exploring its efficacy in different patient populations, its use in combination therapies, and strategies to overcome resistance [8]. This research helps refine treatment guidelines and understand the long-term outcomes for patients taking the drug.
Sources:
1. "Dasatinib." National Cancer Institute.
2. "Sprycel (dasatinib) Tablets." U.S. Food and Drug Administration.
3. DrugPatentWatch.com
4. "FDA Approves First Generic Dasatinib." U.S. Food and Drug Administration.
5. "Generic Drugs: Questions and Answers." U.S. Food and Drug Administration.
6. Renaud, A.C., et al. (2018). Tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Review of Hematology, 11(10), 851-863.
7. C711470. "Chronic Myeloid Leukemia Treatment." National Comprehensive Cancer Network.
8. "Dasatinib." ClinicalTrials.gov.